<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <meta http-equiv="Content-Security-Policy" content="default-src 'self'; script-src 'self'; style-src 'self' 'unsafe-inline' https://fonts.googleapis.com; font-src 'self' https://fonts.gstatic.com; img-src 'self' data: https:; frame-src https://www.youtube.com https://www.google.com; connect-src 'self';" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <title>Zepbound &amp; GLP-1 Medications for Sleep Apnea | Capital ENT</title>
  <meta name="description" content="Learn how Zepbound (tirzepatide) and GLP-1 medications treat obstructive sleep apnea. Capital ENT reviews the FDA approval, clinical trial results, and what patients should know." />
  <meta name="robots" content="index, follow" />
  <link rel="canonical" href="https://www.capitalent.com/glp1-sleep-apnea.html" />
  <meta property="og:type" content="article" />
  <meta property="og:site_name" content="Capital ENT &amp; Sinus Center" />
  <meta property="og:title" content="Zepbound &amp; GLP-1 Medications for Sleep Apnea | Capital ENT" />
  <meta property="og:description" content="Learn how Zepbound (tirzepatide) and GLP-1 medications treat obstructive sleep apnea. Capital ENT reviews the FDA approval, clinical trial results, and what patients should know." />
  <meta property="og:url" content="https://www.capitalent.com/glp1-sleep-apnea.html" />
  <meta property="og:image" content="https://www.capitalent.com/CENT-Horizontal-Color.png" />
  <meta name="twitter:card" content="summary_large_image" />
  <meta name="twitter:title" content="Zepbound &amp; GLP-1 Medications for Sleep Apnea | Capital ENT" />
  <meta name="twitter:description" content="Learn how Zepbound (tirzepatide) and GLP-1 medications treat obstructive sleep apnea. Capital ENT reviews the FDA approval, clinical trial results, and what patients should know." />
  <meta name="twitter:image" content="https://www.capitalent.com/CENT-Horizontal-Color.png" />
  <link rel="icon" href="favicon.ico" sizes="any" /><link rel="icon" type="image/png" sizes="32x32" href="favicon-32.png" /><link rel="icon" type="image/png" sizes="16x16" href="favicon-16.png" /><link rel="icon" type="image/png" sizes="256x256" href="favicon.png" /><link rel="apple-touch-icon" sizes="256x256" href="favicon.png" />
  <link rel="preconnect" href="https://fonts.googleapis.com"><link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
  <link href="https://fonts.googleapis.com/css2?family=Instrument+Serif:ital@0;1&family=Inter:wght@400;500;600;700;800&display=swap" rel="stylesheet">
  <link rel="stylesheet" href="style.css">
  <style>
    .references{max-width:1100px;margin:0 auto;padding:0 40px}
    .references h3{font-size:16px;font-weight:700;color:var(--navy);margin-bottom:16px;font-family:var(--serif)}
    .references ol{list-style:decimal;padding-left:24px;display:flex;flex-direction:column;gap:10px}
    .references li{font-size:13px;color:var(--gray);line-height:1.6}
    .references li em{font-style:italic}
    @media(max-width:600px){.references{padding:0 20px}}
  </style>
  <script type="application/ld+json">{"@context":"https://schema.org","@graph":[{"@type":"MedicalOrganization","@id":"https://www.capitalent.com/#organization","name":"Capital ENT & Sinus Center","url":"https://www.capitalent.com","logo":"https://www.capitalent.com/CENT-Horizontal-Color.png","telephone":"+15123394040","medicalSpecialty":"Otolaryngology","sameAs":["https://www.facebook.com/capitalENT.otolaryngology/","https://www.youtube.com/@capitalentsinuscenter189","https://www.instagram.com/capitalentandsinus/","https://www.tiktok.com/@capitalentsinuscenter"],"aggregateRating":{"@type":"AggregateRating","ratingValue":"4.9","reviewCount":"500","bestRating":"5","worstRating":"1"}},{"@type":"MedicalWebPage","@id":"https://www.capitalent.com/glp1-sleep-apnea.html#webpage","url":"https://www.capitalent.com/glp1-sleep-apnea.html","name":"Zepbound & GLP-1 Medications for Sleep Apnea | Capital ENT","description":"Learn how Zepbound (tirzepatide) and GLP-1 medications treat obstructive sleep apnea. Capital ENT reviews the FDA approval, clinical trial results, and what patients should know.","isPartOf":{"@id":"https://www.capitalent.com/#organization"},"about":{"@type":"MedicalCondition","name":"Obstructive Sleep Apnea","alternateName":["OSA","Sleep-Disordered Breathing"]},"specialty":"Otolaryngology","medicalAudience":{"@type":"Patient"},"lastReviewed":"2026-02-28","reviewedBy":{"@type":"Physician","name":"Raymond J. Brown, MD","memberOf":{"@id":"https://www.capitalent.com/#organization"}}},{"@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.capitalent.com/"},{"@type":"ListItem","position":2,"name":"Sleep","item":"https://www.capitalent.com/sleep.html"},{"@type":"ListItem","position":3,"name":"GLP-1 Medications for Sleep Apnea","item":"https://www.capitalent.com/glp1-sleep-apnea.html"}]},
    {"@type": "FAQPage", "mainEntity": [{"@type": "Question", "name": "Is Zepbound FDA-approved for sleep apnea?", "acceptedAnswer": {"@type": "Answer", "text": "Yes. In 2024, Zepbound (tirzepatide) became the first medication FDA-approved specifically for treating moderate to severe obstructive sleep apnea in adults with obesity. The approval was based on the SURMOUNT-OSA clinical trials, which showed significant reductions in sleep apnea severity over 52 weeks."}}, {"@type": "Question", "name": "Can I stop using my CPAP if I start Zepbound?", "acceptedAnswer": {"@type": "Answer", "text": "The clinical trials did not evaluate when or whether it is appropriate to discontinue CPAP therapy. While 42-50% of trial participants achieved mild or remission-level sleep apnea, any changes to your CPAP use should be made in consultation with your sleep medicine provider and guided by follow-up sleep testing."}}, {"@type": "Question", "name": "What is the difference between Zepbound, Mounjaro, and Ozempic?", "acceptedAnswer": {"@type": "Answer", "text": "Zepbound and Mounjaro contain the same active ingredient (tirzepatide), a dual GIP/GLP-1 receptor agonist. Zepbound is FDA-approved for obesity and now for OSA in adults with obesity, while Mounjaro is approved only for type 2 diabetes. Ozempic (semaglutide) is a GLP-1 receptor agonist approved for type 2 diabetes and cardiovascular risk reduction, but not for OSA."}}, {"@type": "Question", "name": "How effective is Zepbound for sleep apnea?", "acceptedAnswer": {"@type": "Answer", "text": "In clinical trials, Zepbound reduced sleep apnea severity (AHI) by 50-59% over 52 weeks. Approximately 42-50% of participants achieved mild or remission-level sleep apnea. Patients also experienced significant weight loss (17-20%), reductions in blood pressure, and lower inflammation markers."}}, {"@type": "Question", "name": "Does Capital ENT prescribe GLP-1 medications for sleep apnea?", "acceptedAnswer": {"@type": "Answer", "text": "Capital ENT's board-certified otolaryngologists can evaluate your sleep apnea, discuss whether weight-loss medications like Zepbound may be appropriate as part of your treatment plan, and coordinate care with your primary care physician or endocrinologist. Comprehensive sleep apnea management often involves multiple treatment approaches tailored to each patient."}}]}
  ]}</script>
</head>
<body>
<a href="#main-content" class="skip-link">Skip to main content</a>
<div class="util-bar"><div class="util-phones"><span><b>Austin:</b> <a href="tel:5123394040">512-339-4040</a></span><span><b>Lakeway:</b> <a href="tel:5126824798">512-682-4798</a></span><span><b>Marble Falls:</b> <a href="tel:5123394040">512-339-4040</a></span><span><b>Dripping Springs:</b> <a href="tel:5123394040">512-339-4040</a></span></div><div class="util-actions"><a href="https://www.capitalent.com/patient-portal/" target="_blank" rel="noopener">Patient Portal</a><a href="make-a-payment.html">Pay Bill</a></div></div>
<div class="navbar">
  <div class="nav-logo"><a href="index.html"><picture><source srcset="CENT-Horizontal-Color.webp" type="image/webp" /><img src="CENT-Horizontal-Color.png" alt="Capital ENT &amp; Sinus Center" /></picture></a></div>
  <nav class="main-nav">
    <a href="index.html">Home</a>
    <div class="nav-dd"><button class="nav-dd-trigger" aria-expanded="false" aria-haspopup="true">What We Treat <svg class="nav-chevron" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2.5" aria-hidden="true"><polyline points="6 9 12 15 18 9"/></svg></button><div class="nav-dd-menu" role="menu"><div class="nav-dd-list"><a href="nose-sinus.html">Nasal Obstruction &amp; Sinusitis</a><a href="sleep.html">Snoring &amp; Sleep Apnea</a><a href="allergy.html">Allergies</a><a href="pediatric-ent.html">Pediatric ENT</a><a href="ear-care.html">Hearing Loss &amp; Ear Conditions</a><a href="throat.html">Throat &amp; Voice Problems</a></div></div></div>
    <div class="nav-dd"><button class="nav-dd-trigger" aria-expanded="false" aria-haspopup="true">Solutions <svg class="nav-chevron" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2.5" aria-hidden="true"><polyline points="6 9 12 15 18 9"/></svg></button><div class="nav-dd-menu" role="menu"><div class="nav-dd-mega"><div class="nav-dd-col"><span class="nav-dd-cat">Nasal &amp; Sinus</span><a href="balloon-sinuplasty.html">Balloon Sinuplasty</a><a href="septoplasty.html">Septoplasty</a><a href="turbinate-reduction.html">Turbinate Reduction</a><a href="nasal-valve-repair.html">Nasal Valve Repair</a><a href="nasal-cryotherapy.html">Nasal Cryotherapy</a><a href="polypectomy.html">Polypectomy</a></div><div class="nav-dd-col"><span class="nav-dd-cat">Ear &amp; Hearing</span><a href="ear-tubes.html">Ear Tubes</a><a href="eustachian-tube-dilation.html">Eustachian Tube Dilation</a><a href="hearing-aids.html">Hearing Aids</a><span class="nav-dd-cat">Throat &amp; Sleep</span><a href="tonsillectomy.html">Tonsillectomy</a><a href="snoreplasty.html">Snoreplasty</a><a href="uvulectomy.html">Uvulectomy</a><a href="cpap.html">CPAP Therapy</a><a href="cpap-alternatives.html">CPAP Alternatives</a><a href="inspire.html">Inspire Therapy</a><a href="at-home-sleep-study.html">At-Home Sleep Study</a><span class="nav-dd-cat">Allergy &amp; Other</span><a href="allergy-shots-drops.html">Allergy Shots &amp; Drops</a><a href="ct-scanner.html">In-Office CT Scanner</a><a href="ent-urgent-care.html">ENT Urgent Care</a></div></div></div></div>
    <a href="our-providers.html">Our Providers</a><a href="locations.html">Locations</a>
    <div class="nav-dd"><button class="nav-dd-trigger" aria-expanded="false" aria-haspopup="true">Patients <svg class="nav-chevron" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2.5" aria-hidden="true"><polyline points="6 9 12 15 18 9"/></svg></button><div class="nav-dd-menu" role="menu"><div class="nav-dd-list"><a href="faq.html">FAQ</a><a href="patient-resources.html">Patient Resources</a><a href="post-op-care.html">Post-Op Care</a><a href="insurance.html">Insurance &amp; Billing</a><a href="reviews.html">Patient Reviews</a><a href="ask-the-ent.html">Ask the ENT</a><a href="videos.html">ENT Videos</a></div></div></div>
    <a href="#" class="nav-book" data-action="book">Request Appointment</a>
  </nav>
  <button class="hamburger" id="hamburgerBtn" aria-label="Open menu" aria-expanded="false"><span></span><span></span><span></span></button>
</div>
<div class="mobile-nav" id="mobileNav" role="dialog" aria-modal="true" aria-label="Navigation menu">
  <div class="mobile-nav-overlay" id="mobileNavOverlay"></div>
  <div class="mobile-nav-drawer">
    <div class="mobile-nav-header"><picture><source srcset="CENT-Horizontal-Color.webp" type="image/webp" /><img src="CENT-Horizontal-Color.png" alt="Capital ENT &amp; Sinus Center" /></picture><button class="mobile-nav-close" id="mobileNavClose" aria-label="Close menu">&times;</button></div>
    <nav class="mobile-nav-links">
      <a href="index.html">Home</a>
      <span class="mobile-nav-section">What We Treat</span>
      <a href="nose-sinus.html">Nasal Obstruction &amp; Sinusitis</a><a href="sleep.html">Snoring &amp; Sleep Apnea</a><a href="allergy.html">Allergies</a><a href="pediatric-ent.html">Pediatric ENT</a><a href="ear-care.html">Hearing Loss &amp; Ear Conditions</a><a href="throat.html">Throat &amp; Voice Problems</a>
      <span class="mobile-nav-section">Solutions</span>
      <a href="balloon-sinuplasty.html">Balloon Sinuplasty</a>
      <a href="septoplasty.html">Septoplasty</a>
      <a href="turbinate-reduction.html">Turbinate Reduction</a>
      <a href="nasal-valve-repair.html">Nasal Valve Repair</a>
      <a href="nasal-cryotherapy.html">Nasal Cryotherapy</a>
      <a href="polypectomy.html">Polypectomy</a>
      <a href="ear-tubes.html">Ear Tubes</a>
      <a href="eustachian-tube-dilation.html">Eustachian Tube Dilation</a>
      <a href="hearing-aids.html">Hearing Aids</a>
      <a href="tonsillectomy.html">Tonsillectomy</a>
      <a href="snoreplasty.html">Snoreplasty</a>
      <a href="uvulectomy.html">Uvulectomy</a>
      <a href="cpap.html">CPAP Therapy</a>
      <a href="cpap-alternatives.html">CPAP Alternatives</a>
      <a href="inspire.html">Inspire Therapy</a>
      <a href="at-home-sleep-study.html">At-Home Sleep Study</a>
      <a href="allergy-shots-drops.html">Allergy Shots &amp; Drops</a>
      <a href="ct-scanner.html">In-Office CT Scanner</a>
      <a href="ent-urgent-care.html">ENT Urgent Care</a>
      <span class="mobile-nav-section">Practice</span>
      <a href="our-providers.html">Our Providers</a>
      <a href="locations.html">Locations</a>
      <span class="mobile-nav-section">Patients</span><a href="faq.html">FAQ</a><a href="patient-resources.html">Patient Resources</a><a href="post-op-care.html">Post-Op Care</a><a href="insurance.html">Insurance &amp; Billing</a><a href="reviews.html">Patient Reviews</a><a href="ask-the-ent.html">Ask the ENT</a><a href="videos.html">ENT Videos</a>
    </nav>
    <div class="mobile-nav-footer"><a href="tel:5123394040"><svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2.2"><path d="M22 16.92v3a2 2 0 01-2.18 2A19.79 19.79 0 013.09 5.18 2 2 0 015.07 3h3a2 2 0 012 1.72c.127.96.361 1.903.7 2.81a2 2 0 01-.45 2.11L9.09 10.91a16 16 0 006 6l1.27-1.27a2 2 0 012.11-.45c.907.339 1.85.573 2.81.7A2 2 0 0122 17.92z"/></svg>Call 512-339-4040</a></div>
  </div>
</div>
<main id="main-content">

<section class="page-hero"><div class="page-hero-inner">
  <span class="eyebrow">Sleep Medicine</span>
  <h1>Zepbound &amp; GLP-1 Medications for Obstructive Sleep Apnea</h1>
  <p>Zepbound (tirzepatide) is the first FDA-approved medication for treating obstructive sleep apnea in adults with obesity. In landmark clinical trials, it reduced sleep apnea severity by 50-59% and helped nearly half of participants reach mild or remission-level disease. Here's what you need to know about this new treatment option and how it fits into comprehensive sleep apnea care.</p>
  <div class="hero-btns">
    <a href="#" class="btn-red" data-action="book"><svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2.2"><rect x="3" y="4" width="18" height="18" rx="2"/><line x1="16" y1="2" x2="16" y2="6"/><line x1="8" y1="2" x2="8" y2="6"/><line x1="3" y1="10" x2="21" y2="10"/></svg>Request an Appointment</a>
    <a href="tel:5123394040" class="btn-ghost"><svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2.2"><path d="M22 16.92v3a2 2 0 01-2.18 2A19.79 19.79 0 013.09 5.18 2 2 0 015.07 3h3a2 2 0 012 1.72c.127.96.361 1.903.7 2.81a2 2 0 01-.45 2.11L9.09 10.91a16 16 0 006 6l1.27-1.27a2 2 0 012.11-.45c.907.339 1.85.573 2.81.7A2 2 0 0122 17.92z"/></svg>Call 512-339-4040</a>
  </div>
</div></section>
<div class="breadcrumb"><div class="breadcrumb-inner"><a href="index.html">Home</a><span>›</span><a href="sleep.html">Sleep</a><span>›</span><span>GLP-1 Medications for Sleep Apnea</span></div></div>

<!-- WHAT IS ZEPBOUND -->
<section class="section"><div class="section-inner"><div class="info-split">
  <div class="info-copy">
    <span class="eyebrow">FDA-Approved Treatment</span>
    <h2>What Is Zepbound?</h2>
    <p>Zepbound (tirzepatide) is a once-weekly injectable medication that became the first drug FDA-approved specifically for treating moderate to severe obstructive sleep apnea (OSA) in adults with obesity. It is used in combination with a reduced-calorie diet and increased physical activity.</p>
    <p>Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist — meaning it activates two hormone pathways involved in appetite regulation and metabolism. While it is often grouped with "GLP-1 medications," it is technically a dual agonist that works through both GIP and GLP-1 receptors.</p>
    <ul class="check-list">
      <li>First medication FDA-approved specifically for OSA</li>
      <li>Once-weekly subcutaneous injection</li>
      <li>Dual GIP/GLP-1 receptor agonist (not a pure GLP-1 drug)</li>
      <li>Approved for moderate to severe OSA in adults with obesity</li>
    </ul>
  </div>
  <div class="info-visual"><div class="info-visual-inner">
    <div class="allergy-visual-head">
      <div class="allergy-visual-icon-wrap"><svg width="22" height="22" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><path d="M21 12.79A9 9 0 1111.21 3 7 7 0 0021 12.79z"/></svg></div>
      <span class="allergy-visual-label">SURMOUNT-OSA Results</span>
    </div>
    <div class="allergy-stats-pair">
      <div class="allergy-stat"><span class="num">50–59%</span><span class="lbl">Reduction in AHI (Sleep Apnea Severity)</span></div>
      <div class="allergy-stat"><span class="num">42–50%</span><span class="lbl">Achieved Mild or Remission-Level OSA</span></div>
    </div>
    <div class="allergy-stats-pair">
      <div class="allergy-stat"><span class="num">17–20%</span><span class="lbl">Body Weight Reduction Over 52 Weeks</span></div>
      <div class="allergy-stat"><span class="num">56%</span><span class="lbl">Reduction in All-Cause Mortality (Real-World Data)</span></div>
    </div>
    <p class="allergy-visual-note">Based on the SURMOUNT-OSA trials (469 participants, 52 weeks) and a retrospective study of 42,300 patients.</p>
  </div></div>
</div></div></section>

<!-- THE CLINICAL EVIDENCE -->
<section class="section bg-off"><div class="section-inner">
  <div class="section-head"><span class="eyebrow">The Evidence</span><h2>What the Clinical Trials Show</h2><div class="rule"></div></div>
  <div class="conditions-grid">
    <div class="cond-card"><div class="cond-icon"><svg viewBox="0 0 24 24"><path d="M22 11.08V12a10 10 0 11-5.93-9.14"/><polyline points="22 4 12 14.01 9 11.01"/></svg></div>
      <h3>SURMOUNT-OSA: The Landmark Trials</h3>
      <p>The FDA approval was based on two phase 3 randomized controlled trials published in the New England Journal of Medicine, enrolling 469 adults with moderate-to-severe OSA (AHI of 15 or more events per hour) and obesity (BMI of 30 or above) across 60 sites in nine countries. Participants received tirzepatide or placebo for 52 weeks. In patients not using PAP therapy, tirzepatide reduced AHI by 25.3 events per hour versus 5.3 with placebo. In patients continuing PAP therapy, the reduction was 29.3 versus 5.5 events per hour.</p>
    </div>
    <div class="cond-card"><div class="cond-icon"><svg viewBox="0 0 24 24"><path d="M22 12h-4l-3 9L9 3l-3 9H2"/></svg></div>
      <h3>Benefits Beyond Sleep Apnea</h3>
      <p>Beyond reducing sleep apnea severity, trial participants experienced significant improvements in other health markers. Body weight decreased by 17.7-19.6% with tirzepatide versus 1.6-2.3% with placebo. Patients also saw meaningful reductions in systolic blood pressure, hypoxic burden (the amount of oxygen deprivation during sleep), and high-sensitivity C-reactive protein, a marker of inflammation linked to cardiovascular risk.</p>
    </div>
    <div class="cond-card"><div class="cond-icon"><svg viewBox="0 0 24 24"><circle cx="12" cy="12" r="10"/><path d="M16 16s-1.5-2-4-2-4 2-4 2"/><line x1="9" y1="9" x2="9.01" y2="9"/><line x1="15" y1="9" x2="15.01" y2="9"/></svg></div>
      <h3>Side Effects</h3>
      <p>The most common adverse events were gastrointestinal — including diarrhea, nausea, and vomiting — typically mild to moderate in severity and occurring primarily during the dose escalation period. These side effects are consistent with the known profile of GLP-1-based medications and generally improve as the body adjusts to the medication.</p>
    </div>
  </div>
</div></section>

<!-- HOW IT COMPARES TO OTHER TREATMENTS -->
<section class="section"><div class="section-inner">
  <div class="section-head"><span class="eyebrow">Comparing Approaches</span><h2>How Tirzepatide Compares to Other Treatments</h2><div class="rule"></div></div>
  <div class="info-copy" style="max-width:800px">
    <p>Network meta-analyses comparing different medication-based approaches have consistently demonstrated tirzepatide's advantages for OSA treatment. Tirzepatide produced the greatest reduction in AHI (approximately 21.9 events per hour) compared to GLP-1 receptor agonists alone (approximately 5.2 events per hour) and SGLT-2 inhibitors (approximately 7.7 events per hour), along with the most substantial decreases in body weight and blood pressure.</p>
    <p>Among other GLP-1 receptor agonists, liraglutide has demonstrated some efficacy in reducing sleep-disordered breathing events, though the effect appears smaller than that observed with tirzepatide. A large comparative study of patients with obesity, type 2 diabetes, and OSA found that tirzepatide demonstrated superior reductions in mortality risk compared to both SGLT-2 inhibitors and GLP-1 receptor agonists.</p>
    <p>It is important to note that other commonly known medications in this class have different FDA-approved indications. Ozempic (semaglutide) is approved for type 2 diabetes management and cardiovascular risk reduction, but not for OSA. Mounjaro contains the same active ingredient as Zepbound (tirzepatide), but is approved only for type 2 diabetes — not for sleep apnea or weight management.</p>
    <p>Current clinical guidance recommends that anti-obesity medications and bariatric surgery are more effective than lifestyle interventions alone for achieving weight loss in OSA patients. Most patients achieve 15-20% weight loss in one year with optimal use of incretin-based medications. A comprehensive review of pharmacotherapy for OSA concluded that weight-loss agents, particularly tirzepatide, represent the most promising medication-based treatment option available.</p>
  </div>
</div></section>

<!-- WHAT PATIENTS SHOULD KNOW -->
<section class="section bg-off"><div class="section-inner">
  <div class="section-head"><span class="eyebrow">For Patients</span><h2>What You Should Know Before Starting Treatment</h2><div class="rule"></div></div>
  <div class="why-grid">
    <div class="why-card"><div class="why-icon"><svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><circle cx="12" cy="12" r="10"/><path d="M12 16v-4"/><path d="M12 8h.01"/></svg></div><h3>Start With a Diagnosis</h3><p>Zepbound is approved specifically for moderate to severe OSA in adults with obesity. Before considering this treatment, you need an accurate diagnosis of your sleep apnea severity through a sleep study. An ENT evaluation can also identify whether anatomic factors like nasal obstruction or enlarged tonsils are contributing to your condition.</p><span class="why-avail">At-Home Sleep Testing Available</span></div>
    <div class="why-card"><div class="why-icon"><svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><path d="M22 12h-4l-3 9L9 3l-3 9H2"/></svg></div><h3>Don't Stop CPAP on Your Own</h3><p>The clinical trials did not evaluate when or how to discontinue PAP therapy. While many participants achieved significantly milder sleep apnea, any changes to your CPAP use should be guided by your sleep medicine provider and confirmed with follow-up sleep testing. Improvement can begin as early as 4 weeks, but statistically significant results were not seen until about 20 weeks.</p><span class="why-avail">CPAP Management</span></div>
    <div class="why-card"><div class="why-icon"><svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><path d="M17 21v-2a4 4 0 00-4-4H5a4 4 0 00-4 4v2"/><circle cx="9" cy="7" r="4"/><path d="M23 21v-2a4 4 0 00-3-3.87"/><path d="M16 3.13a4 4 0 010 7.75"/></svg></div><h3>Part of a Comprehensive Plan</h3><p>Weight-loss medications work best as one part of a broader treatment plan. Your ENT can evaluate whether anatomic issues — such as a deviated septum, enlarged turbinates, or tongue base obstruction — are contributing to your OSA. For many patients, combining medical and surgical approaches produces the best outcomes.</p><span class="why-avail">Personalized Treatment Plans</span></div>
  </div>
</div></section>

<!-- REAL-WORLD EVIDENCE -->
<section class="section"><div class="section-inner"><div class="info-split reverse">
  <div class="info-copy">
    <span class="eyebrow">Beyond the Trials</span>
    <h2>Real-World Evidence &amp; Long-Term Outlook</h2>
    <p>Emerging real-world data reinforces the clinical trial findings. A large retrospective study of 42,300 patients with OSA and obesity found that tirzepatide was associated with a 56% reduction in all-cause mortality, along with significant reductions in major cardiovascular events and major kidney events compared to lifestyle interventions alone. These benefits were consistent across most patient groups regardless of age, sex, BMI, or CPAP use.</p>
    <p>Research into the time course of improvement shows that measurable reductions in sleep apnea begin as early as week 4 of treatment, though the treatment difference compared to placebo does not become statistically significant until approximately week 20. The magnitude of AHI improvement correlates with weight loss, and studies suggest that treating both sleep-disordered breathing and obesity together is important for optimizing heart and metabolic health benefits.</p>
    <ul class="check-list">
      <li>Real-world mortality reduction of 56% compared to lifestyle changes alone</li>
      <li>Benefits consistent regardless of age, sex, BMI, or CPAP use</li>
      <li>Improvements in cardiovascular and kidney outcomes</li>
      <li>AHI reductions begin as early as week 4 of treatment</li>
    </ul>
  </div>
  <div class="info-visual green"><div class="info-visual-inner">
    <div class="allergy-visual-head">
      <div class="allergy-visual-icon-wrap"><svg width="22" height="22" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><path d="M22 12h-4l-3 9L9 3l-3 9H2"/></svg></div>
      <span class="allergy-visual-label">Real-World Outcomes</span>
    </div>
    <div class="allergy-stats-pair">
      <div class="allergy-stat"><span class="num">42,300</span><span class="lbl">Patients in Retrospective Study</span></div>
      <div class="allergy-stat"><span class="num">56%</span><span class="lbl">Reduction in All-Cause Mortality</span></div>
    </div>
    <div class="allergy-stats-pair">
      <div class="allergy-stat"><span class="num">~27%</span><span class="lbl">Reduction in Cardiovascular Events</span></div>
      <div class="allergy-stat"><span class="num">~57%</span><span class="lbl">Reduction in Major Kidney Events</span></div>
    </div>
    <p class="allergy-visual-note">Data from a retrospective cohort study comparing tirzepatide to lifestyle interventions alone in patients with OSA and obesity.</p>
  </div></div>
</div></div></section>

<!-- FAQ -->
<section class="section bg-off"><div class="section-inner">
  <div class="section-head"><span class="eyebrow">Common Questions</span><h2>GLP-1 Medications &amp; Sleep Apnea FAQ</h2><div class="rule"></div></div>
  <div class="bsp-faq">
    <div class="bfaq-item"><button class="bfaq-q" aria-expanded="false">Is Zepbound FDA-approved for sleep apnea?<svg class="bfaq-chevron" viewBox="0 0 24 24"><polyline points="6 9 12 15 18 9"/></svg></button><div class="bfaq-a"><div class="bfaq-a-inner"><p>Yes. Zepbound (tirzepatide) became the first medication FDA-approved specifically for treating moderate to severe obstructive sleep apnea in adults with obesity. The approval was based on the SURMOUNT-OSA clinical trials, two phase 3 randomized controlled trials published in the New England Journal of Medicine that demonstrated significant reductions in sleep apnea severity over 52 weeks. The medication is used in combination with a reduced-calorie diet and increased physical activity.</p></div></div></div>
    <div class="bfaq-item"><button class="bfaq-q" aria-expanded="false">Can I stop using my CPAP if I start Zepbound?<svg class="bfaq-chevron" viewBox="0 0 24 24"><polyline points="6 9 12 15 18 9"/></svg></button><div class="bfaq-a"><div class="bfaq-a-inner"><p>The clinical trials did not evaluate the timing or appropriateness of discontinuing positive airway pressure (PAP) therapy. While 42-50% of trial participants achieved an AHI below 15 events per hour with minimal daytime sleepiness — thresholds at which PAP may not be recommended — any changes to your CPAP use should be made in close consultation with your sleep medicine provider and guided by follow-up sleep testing to confirm improvement.</p></div></div></div>
    <div class="bfaq-item"><button class="bfaq-q" aria-expanded="false">What is the difference between Zepbound, Mounjaro, and Ozempic?<svg class="bfaq-chevron" viewBox="0 0 24 24"><polyline points="6 9 12 15 18 9"/></svg></button><div class="bfaq-a"><div class="bfaq-a-inner"><p>Zepbound and Mounjaro both contain tirzepatide, a dual GIP/GLP-1 receptor agonist. However, they are approved for different conditions: Zepbound is FDA-approved for obesity and for moderate to severe OSA in adults with obesity, while Mounjaro is approved only for blood sugar control in type 2 diabetes. Ozempic (semaglutide) is a different medication — a GLP-1 receptor agonist (not a dual agonist) — approved for type 2 diabetes and cardiovascular risk reduction, but not for OSA treatment.</p></div></div></div>
    <div class="bfaq-item"><button class="bfaq-q" aria-expanded="false">How effective is Zepbound for sleep apnea?<svg class="bfaq-chevron" viewBox="0 0 24 24"><polyline points="6 9 12 15 18 9"/></svg></button><div class="bfaq-a"><div class="bfaq-a-inner"><p>In the SURMOUNT-OSA clinical trials, tirzepatide reduced sleep apnea severity (measured by the apnea-hypopnea index, or AHI) by 50-59% from baseline over 52 weeks. The average AHI reduction was 20-24 events per hour compared to placebo. Approximately 42-50% of participants achieved mild or remission-level sleep apnea. Patients also experienced 17-20% body weight loss, reductions in blood pressure, and lower levels of inflammatory markers.</p></div></div></div>
    <div class="bfaq-item"><button class="bfaq-q" aria-expanded="false">Does Capital ENT treat sleep apnea patients interested in GLP-1 medications?<svg class="bfaq-chevron" viewBox="0 0 24 24"><polyline points="6 9 12 15 18 9"/></svg></button><div class="bfaq-a"><div class="bfaq-a-inner"><p>Capital ENT's board-certified otolaryngologists can evaluate your sleep apnea, discuss whether weight-loss medications like Zepbound may be appropriate as part of your treatment plan, and coordinate care with your primary care physician or endocrinologist who may prescribe the medication. Comprehensive sleep apnea management often involves multiple treatment approaches — including CPAP, oral appliances, surgical options, and now weight-loss medications — tailored to each patient's anatomy and needs.</p></div></div></div>
  </div>
</div></section>

<!-- REFERENCES -->
<section class="section" style="padding-top:40px;padding-bottom:40px"><div class="references">
  <h3>References</h3>
  <ol>
    <li>Zepbound (tirzepatide) prescribing information. Food and Drug Administration. Updated February 24, 2026.</li>
    <li>FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.</li>
    <li>Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. <em>N Engl J Med.</em> 2024;391(13):1193-1205. doi:10.1056/NEJMoa2404881.</li>
    <li>Wu JY, Chen CC, Ling Tu W, et al. Clinical impact of tirzepatide on patients with OSA and obesity. <em>Chest.</em> 2025;S0012-3692(25)00436-2. doi:10.1016/j.chest.2025.03.030.</li>
    <li>Yang YT, Hou XZ, Zhang XR, Zhang ZP, Wang SH. Comparative effectiveness and safety of novel antidiabetic agents in the management of obstructive sleep apnea: a systematic review, meta-analysis, and network meta-analysis. <em>Respir Med.</em> 2026;253:108671. doi:10.1016/j.rmed.2026.108671.</li>
    <li>Moiz A, Filion KB, Tsoukas MA, et al. The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions. <em>EClinicalMedicine.</em> 2025;86:103363. doi:10.1016/j.eclinm.2025.103363.</li>
    <li>Malhotra A, Grunstein RR, Azarbarzin A, et al. Tirzepatide for sleep-disordered breathing in SURMOUNT-OSA: time course and association with body weight. <em>Sleep Med.</em> 2025;136:106853. doi:10.1016/j.sleep.2025.106853.</li>
    <li>Malhotra A, Grunstein R, Azarbarzin A, et al. Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial. <em>Nat Med.</em> 2026. doi:10.1038/s41591-025-04071-1.</li>
    <li>Nauck MA, Tuttle KR, Tschöp MH, Blüher M. Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits. <em>Lancet.</em> 2026;S0140-6736(25)02105-1. doi:10.1016/S0140-6736(25)02105-1.</li>
    <li>Tang H, Zhang B, Lu Y, et al. Incretin receptor agonists and CPAP use in adults with diabetes, obesity, and obstructive sleep apnea. <em>JAMA Netw Open.</em> 2025;8(12):e2550978. doi:10.1001/jamanetworkopen.2025.50978.</li>
    <li>Lastra AC, Neborak JM, Mokhlesi B. Diagnosis and treatment of obstructive sleep apnea. <em>JAMA Intern Med.</em> 2025;2837455. doi:10.1001/jamainternmed.2025.2318.</li>
    <li>Luu S, Chan DECY, Marshall NS, et al. Pharmacotherapy for obstructive sleep apnea: a critical review of randomized placebo-controlled trials. <em>Sleep Med Rev.</em> 2025;84:102169. doi:10.1016/j.smrv.2025.102169.</li>
  </ol>
</div></section>

<div class="physician-attr">
  <div class="physician-attr-inner">
    <svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M12 22s8-4 8-10V5l-8-3-8 3v7c0 6 8 10 8 10z"/><path d="m9 12 2 2 4-4"/></svg>
    Reviewed by <a href="our-providers.html">Dr. Raymond Brown</a>, Board-Certified Otolaryngologist
  </div>
</div>

<section class="cta-band"><div class="cta-band-inner">
  <h2>Interested in GLP-1 Treatment for Sleep Apnea?</h2>
  <p>Our board-certified otolaryngologists can evaluate your sleep apnea, discuss all available treatment options including Zepbound, and create a personalized care plan. Same-day and next-day consultations often available.</p>
  <div class="cta-band-btns">
    <a href="#" class="btn-white" data-action="book"><svg width="15" height="15" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2.2"><rect x="3" y="4" width="18" height="18" rx="2"/><line x1="16" y1="2" x2="16" y2="6"/><line x1="8" y1="2" x2="8" y2="6"/><line x1="3" y1="10" x2="21" y2="10"/></svg>Request an Appointment</a>
    <a href="tel:5123394040" class="btn-outline-white"><svg width="15" height="15" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2.2"><path d="M22 16.92v3a2 2 0 01-2.18 2A19.79 19.79 0 013.09 5.18 2 2 0 015.07 3h3a2 2 0 012 1.72c.127.96.361 1.903.7 2.81a2 2 0 01-.45 2.11L9.09 10.91a16 16 0 006 6l1.27-1.27a2 2 0 012.11-.45c.907.339 1.85.573 2.81.7A2 2 0 0122 17.92z"/></svg>Call Austin: 512-339-4040</a>
  </div>
</div></section>
</main>
<footer><div class="footer-grid"><div class="footer-brand"><picture><source srcset="CENT-Horizontal-Color.webp" type="image/webp" /><img src="CENT-Horizontal-Color.png" alt="Capital ENT &amp; Sinus Center" /></picture><p>Austin's most trusted ENT practice — serving patients across Central Texas with board-certified otolaryngologists. Compassionate, personalized care since 1999.</p><p class="footer-formerly">Formerly Capital Otolaryngology</p><div class="social-row">
  <a href="https://www.facebook.com/capitalENT.otolaryngology/" class="social-btn" aria-label="Facebook" target="_blank" rel="noopener noreferrer">
    <svg viewBox="0 0 24 24"><path d="M18 2h-3a5 5 0 00-5 5v3H7v4h3v8h4v-8h3l1-4h-4V7a1 1 0 011-1h3z"/></svg>
  </a>
  <a href="https://www.youtube.com/@capitalentsinuscenter189" class="social-btn" aria-label="YouTube" target="_blank" rel="noopener noreferrer">
    <svg viewBox="0 0 24 24"><path d="M22.54 6.42a2.78 2.78 0 00-1.95-1.96C18.88 4 12 4 12 4s-6.88 0-8.59.46A2.78 2.78 0 001.46 6.42 29 29 0 001 12a29 29 0 00.46 5.58A2.78 2.78 0 003.41 19.6C5.12 20 12 20 12 20s6.88 0 8.59-.46a2.78 2.78 0 001.95-1.95A29 29 0 0023 12a29 29 0 00-.46-5.58zM9.75 15.02V8.98l5.75 3.02-5.75 3.02z"/></svg>
  </a>
  <a href="https://www.instagram.com/capitalentandsinus/" class="social-btn" aria-label="Instagram" target="_blank" rel="noopener noreferrer">
    <svg viewBox="0 0 24 24"><rect x="2" y="2" width="20" height="20" rx="5" ry="5" fill="none" stroke="white" stroke-width="1.8"/><path d="M16 11.37A4 4 0 1112.63 8 4 4 0 0116 11.37z" fill="none" stroke="white" stroke-width="1.8"/><line x1="17.5" y1="6.5" x2="17.51" y2="6.5" stroke="white" stroke-width="2" stroke-linecap="round"/></svg>
  </a>
  <a href="https://www.tiktok.com/@capitalentsinuscenter" class="social-btn" aria-label="TikTok" target="_blank" rel="noopener noreferrer">
    <svg viewBox="0 0 24 24"><path d="M19.59 6.69a4.83 4.83 0 01-3.77-4.25V2h-3.45v13.67a2.89 2.89 0 01-2.88 2.5 2.89 2.89 0 01-2.89-2.89 2.89 2.89 0 012.89-2.89c.28 0 .54.04.79.1v-3.51a6.37 6.37 0 00-.79-.05A6.34 6.34 0 003.15 15.2a6.34 6.34 0 0010.86 4.43v-7.15a8.16 8.16 0 005.58 2.18V11.2a4.85 4.85 0 01-3.77-1.74z" fill="white"/></svg>
  </a>
</div></div><div><h4>Services</h4><ul><li><a href="ear-care.html">Hearing Loss &amp; Ear Conditions</a></li><li><a href="hearing-aids.html">Hearing Aids</a></li><li><a href="nose-sinus.html">Nose &amp; Sinus</a></li><li><a href="balloon-sinuplasty.html">Balloon Sinuplasty</a></li><li><a href="sleep.html">Sleep Apnea</a></li><li><a href="throat.html">Throat</a></li><li><a href="tonsillectomy.html">Tonsillectomy</a></li><li><a href="allergy.html">Allergy Treatment</a></li><li><a href="pediatric-ent.html">Pediatric ENT</a></li><li><a href="ent-urgent-care.html">ENT Urgent Care</a></li></ul></div><div><h4>Information</h4><ul><li><a href="our-providers.html">Meet the Providers</a></li><li><a href="faq.html">FAQ</a></li><li><a href="insurance.html">Insurance &amp; Billing</a></li><li><a href="patient-resources.html">Patient Resources</a></li><li><a href="reviews.html">Patient Reviews</a></li><li><a href="ask-the-ent.html">Ask the ENT</a></li><li><a href="videos.html">ENT Videos</a></li><li><a href="https://www.capitalent.com/patient-portal/" target="_blank" rel="noopener">Patient Portal</a></li><li><a href="make-a-payment.html">Pay Bill</a></li><li><a href="post-op-care.html">Post-Op Care</a></li><li><a href="locations.html">Contact Us</a></li></ul></div><div><h4>Contact</h4><div class="footer-contact-block"><div class="city">Austin</div><div class="phone"><a href="tel:5123394040">512-339-4040</a></div><div class="addr">12309 N Mopac Expy STE 100<br/>Austin, TX 78758</div></div><div class="footer-contact-block"><div class="city">Lakeway</div><div class="phone"><a href="tel:5126824798">512-682-4798</a></div><div class="addr">4 Lakeway Centre Ct Unit B</div></div><div class="footer-contact-block"><div class="city">Marble Falls &amp; Dripping Springs</div><div class="phone"><a href="tel:5123394040">512-339-4040</a></div></div></div></div><div class="footer-bottom"><span>&copy;2026 Capital ENT &amp; Sinus Center &nbsp;|&nbsp; All Rights Reserved</span><span><a href="privacy-policy.html">Privacy Policy</a> &nbsp;&middot;&nbsp; <a href="terms.html">Terms &amp; Conditions</a> &nbsp;&middot;&nbsp; <a href="#">Sitemap</a></span></div></footer>
<a href="#" class="sticky-cta" data-action="book" title="Book an Appointment"><svg viewBox="0 0 24 24"><rect x="3" y="4" width="18" height="18" rx="2"/><line x1="16" y1="2" x2="16" y2="6"/><line x1="8" y1="2" x2="8" y2="6"/><line x1="3" y1="10" x2="21" y2="10"/></svg>Book Appointment</a>
<div id="bookingModal" class="modal" role="dialog" aria-labelledby="bookingModalTitle" aria-hidden="true"><div class="modal-overlay" data-action="close-modal" role="button" tabindex="0" aria-label="Close"></div><div class="modal-content"><button class="modal-close" data-action="close-modal" type="button" aria-label="Close booking form">&times;</button><div class="modal-header"><h2 id="bookingModalTitle">Request an Appointment</h2><p>Fill out the form below and we'll get back to you within 24 hours.</p></div><form id="bookingForm" class="modal-form"><div class="form-group"><label for="fullName">Full Name *</label><input type="text" id="fullName" name="fullName" required placeholder="Jane Smith" aria-required="true"></div><div class="form-group"><label for="email">Email *</label><input type="email" id="email" name="email" required placeholder="jane@example.com" aria-required="true"></div><div class="form-group"><label for="phone">Phone Number *</label><input type="tel" id="phone" name="phone" required placeholder="(512) 000-0000" aria-required="true"></div><div class="form-group"><label for="location">Preferred Location *</label><select id="location" name="location" required aria-required="true"><option value="">Select a location...</option><option value="austin">Austin — 12309 N Mopac Expy</option><option value="lakeway">Lakeway — 4 Lakeway Centre Ct</option><option value="marble_falls">Marble Falls — 801 Steve Hawkins Pkwy</option><option value="dripping_springs">Dripping Springs — 800 US-290</option></select></div><div class="form-group"><label for="service">Service Type *</label><select id="service" name="service" required aria-required="true">
          <option value="">Select a service...</option>
          <option value="ear">Ear Care &amp; Hearing</option>
          <option value="nose">Nose &amp; Sinus</option>
          <option value="sleep" selected>Sleep Medicine / Sleep Apnea</option>
          <option value="throat">Throat &amp; Voice</option>
          <option value="allergy">Allergy Treatment</option>
          <option value="other">Other / Not Sure</option>
</select></div><div class="form-group"><label for="message">Additional Notes</label><textarea id="message" name="message" placeholder="Tell us about your condition (optional)" rows="3"></textarea></div><button type="submit" class="btn-red">Request Appointment</button><p class="form-disclaimer">By submitting this form, you agree to be contacted by Capital ENT at the number provided.</p></form></div></div>
<script src="main.js" defer></script>
<script>
(function(){document.querySelectorAll('.nav-dd').forEach(function(dd){var trigger=dd.querySelector('.nav-dd-trigger');if(!trigger)return;trigger.addEventListener('click',function(e){e.stopPropagation();var open=dd.classList.contains('open');document.querySelectorAll('.nav-dd.open').forEach(function(d){d.classList.remove('open');d.querySelector('.nav-dd-trigger').setAttribute('aria-expanded','false');});if(!open){dd.classList.add('open');trigger.setAttribute('aria-expanded','true');}});dd.addEventListener('mouseleave',function(){dd.classList.remove('open');trigger.setAttribute('aria-expanded','false');});});document.addEventListener('click',function(e){if(!e.target.closest('.nav-dd'))document.querySelectorAll('.nav-dd.open').forEach(function(d){d.classList.remove('open');d.querySelector('.nav-dd-trigger').setAttribute('aria-expanded','false');});});document.addEventListener('keydown',function(e){if(e.key==='Escape')document.querySelectorAll('.nav-dd.open').forEach(function(d){d.classList.remove('open');d.querySelector('.nav-dd-trigger').setAttribute('aria-expanded','false');});});})();
</script>
</body>
</html>